Jan G. J. Van De Winkel

Jan G. J. Van De Winkel's AcademicInfluence.com Rankings

Biology

#15467

World Rank

#19449

Historical Rank

Immunology

#1066

World Rank

#1092

Historical Rank

biology Degrees

Download Badge

Biology

Jan G. J. Van De Winkel's Degrees

PhD Immunology University of Amsterdam
Masters Biology University of Amsterdam

Similar Degrees You Can Earn

Best Online Master's in Biology

Why Is Jan G. J. Van De Winkel Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Jan G. J. Van De Winkel's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Impaired IgG-Dependent Anaphylaxis and Arthus Reaction in FcγRIII (CD16) Deficient Mice (1996) (459)
Biology of Human Immunoglobulin G Fc Receptors (1991) (401)
Therapeutic IgG4 antibodies engage in Fab-arm exchange with endogenous human IgG4 in vivo (2009) (255)
FcαRI-positive liver Kupffer cells: Reappraisal of the function of immunoglobulin A in immunity (2000) (253)
FcgammaR polymorphisms: Implications for function, disease susceptibility and immunotherapy. (2003) (246)
Clinical significance of IgG Fc receptors and FcγR-directed immunotherapies (1997) (231)
IgG receptor polymorphisms: risk factors for disease (1998) (193)
Fcã Receptor Iia (Cd32) Polymorphism In Fulminant Meningococcal Septic (1994) (179)
Fcã Receptor Iia (Cd32) Heterogeneity In Patients With Recurrent Bacterial Respiratory Tract Infections (1994) (166)
FcαRI (CD89) as a Novel Trigger Molecule for Bispecific Antibody Therapy (1997) (124)
Human Immunoglobulin A Receptor (FcRI, CD89) Function in Transgenic Mice Requires Both FcR γ Chain and CR3 (CD11b/CD18) (1999) (123)
Involvement of the high-affinity receptor for IgG (Fc gamma RI; CD64) in enhanced tumor cell cytotoxicity of neutrophils during granulocyte colony-stimulating factor therapy (1993) (121)
Clinical Relevance of Fcγ Receptor Polymorphisms (1997) (109)
Anti-galactose-α-1,3-galactose IgE from allergic patients does not bind α-galactosylated glycans on intact therapeutic antibody Fc domains (2011) (102)
Resolution of cutaneous inflammation after local elimination of macrophages (2000) (98)
Immunotherapeutic perspective for bispecific antibodies. (2000) (90)
The FcγRIa (CD64) Ligand Binding Chain Triggers Major Histocompatibility Complex Class II Antigen Presentation Independently of Its Associated FcR γ-Chain (1999) (86)
A novel PCR-based method for direct Fcγ receptor IIIa (CD16) allotyping (2000) (72)
Differential binding to human FcγRIIa and FcγRIIb receptors by human IgG wildtype and mutant antibodies (2003) (72)
Human antibodies as next generation therapeutics. (2001) (69)
Effective Phagocytosis and Killing of Candida albicans via Targeting FcγRI (CD64) or FcαRI (CD89) on Neutrophils (1999) (69)
Evidence for non-random distribution of Fcγ receptor genotype combinations (2003) (60)
Fcγ receptor expression levels on monocytes are elevated in rheumatoid arthritis patients with high erythrocyte sedimentation rate who do not use anti‐rheumatic drugs (2003) (60)
CD16 on human γδ T lymphocytes: Expression, function, and specificity for mouse IgG isotypes (1992) (59)
Anti‐GPIIb/IIIa (CD41) monoclonal antibody‐induced platelet activation requires Fc receptor‐dependent cell‐cell interaction (1991) (56)
Severity of Guillain–Barré syndrome is associated with Fcγ Receptor III polymorphisms (2005) (53)
Enhancement of Polymorphonuclear Cell-mediated Tumor Cell Killing on Simultaneous Engagement of FcγRI (CD64) and FcαRI (CD89) (2001) (52)
Cross‐linking of Both Types of IgG Fc Receptors, FcγyRI and FcγyRII, Enhances Intracellular Free Ca2+ in the Monocytic Cell Line U937 (1990) (52)
Human IgA Fc receptors (FcαR) (1998) (50)
The novel tribody [(CD20)2xCD16] efficiently triggers effector cell-mediated lysis of malignant B cells (2013) (49)
The Immunoglobulin Receptors and their Physiological and Pathological Roles in Immunity (1998) (47)
Characterization of Two Fc Receptors for Mouse Immunoglobulins on Human Monocytes and Cell Lines (1987) (45)
Human C-reactive protein does not bind to fcγRIIa on phagocyti cells (2001) (41)
Activity of Two Types of Fc Receptors, FcγRI and FcγRII, in Human Monocyte Cytotoxicity to Sensitized Erythrocytes (1989) (40)
The human Fc receptor for IgA (FcαRI, CD89) on transgenic peritoneal macrophages triggers phagocytosis and tumor cell lysis (1999) (40)
Fusion proteins between ligands for NKG2D and CD20-directed single-chain variable fragments sensitize lymphoma cells for natural killer cell-mediated lysis and enhance antibody-dependent cellular cytotoxicity (2012) (37)
Human Fcγ receptor II: a standby receptor activated by proteolysis? (1990) (33)
Synergism of interleukin 6 and 1α,25‐dihydroxyvitamin D3 in induction of myeloid differentiation of human leukemic cell lines (1992) (31)
Polymorphism of the Human Fcγ Receptor II (CD32): Molecular Basis and Functional Aspects (1992) (29)
Heparin-Induced Thrombocytopenia : New Insights Into the Impact of the Fc g RIIa-RH 131 Polymorphism (1998) (27)
Fcγ receptor polymorphisms and periodontal status: a prospective follow‐up study (2006) (27)
Leukocyte and complement activation by GM1-specific antibodies is associated with acute motor axonal neuropathy in rabbits (2007) (26)
Ofatumumab, a Human Mab Targeting a Membrane-Proximal Small-Loop Epitope On CD20, Induces Potent NK Cell-Mediated ADCC. (2009) (26)
Alternatively spliced forms of the human myeloid Fcα receptor (CD89) in neutrophils (2004) (26)
A novel polymorphism of FcαRI (CD89) associated with aggressive periodontitis (2004) (26)
A novel human CD32 mAb blocks experimental immune haemolytic anaemia in FcγRIIA transgenic mice (2005) (25)
A Human FcγRI/CD64 Transgenic Model for In Vivo Analysis of (Bispecific) Antibody Therapeutics (1995) (24)
Identification of Signaling Motifs Within Human FcyRIIa and FcyRIIb Isoforms (2000) (22)
FcγRIa–γ‐chain complexes trigger antibody‐dependent cell‐mediated cytotoxicity (ADCC) in CD5+ B cell/macrophage IIA1.6 cells (1998) (21)
Selective Enhancement of Leu Cam Expression by Interleukin 6 during Differentiation of Human Promonocytic U937 Cells (1991) (20)
Neutrophil FcγRI as Target for Immunotherapy of Invasive Candidiasis (2001) (18)
In situ depletion of CD4+ T cells in human skin by Zanolimumab (2007) (18)
Binding of Submaximal C1q to B Cells Opsonized with Anti-CD20 Mabs Ofatumumab (OFA) or Rituximab (RTX) Promotes Complement Dependent Cytotoxicity (CDC), and Considerably Higher Levels of CDC Are Induced by OFA Than by RTX. (2008) (15)
Direct targeting of genetically modified tumour cells to FcγRI triggers potent tumour cytotoxicity (2006) (15)
Chemotherapy-Refractory Diffuse Large B-Cell Lymphomas (DLBCL) Are Effectively Killed by Ofatumumab-Induced Complement-Mediated Cytoxicity. (2007) (15)
No association of FcγRIIa, FcγRIIIa and FcγRIIIb polymorphisms with MS (2003) (14)
Daratumumab, a Novel Potent Human Anti-CD38 Monoclonal Antibody, Induces Significant Killing of Human Multiple Myeloma Cells: Therapeutic Implication. (2009) (14)
A SINGLE INJECTION OF POLYETHYLENE-GLYCOL GRANULOCYTE COLONY-STIMULATING FACTOR STRONGLY PROLONGS SURVIVAL OF MICE WITH SYSTEMIC CANDIDIASIS (2000) (13)
214 POSTER Characterization of a recombinant, fully human monoclonal antibody directed against the human insulin-like growth factor-1 receptor (2006) (13)
Size-dependent effect of IgA on the IgA Fc receptor (CD89) (1997) (12)
Fc receptors: Role in biology and antibody therapy (2010) (12)
Flow cytometric determination of FcγRIIa (CD32) polymorphism (2004) (11)
Isotype‐specific cross‐linking of select human FcγR isoforms triggers release of IL‐6 (1993) (10)
The Fc g RIa (CD64) Ligand Binding Chain Triggers Major Histocompatibility Complex Class II Antigen Presentation Independently of Its Associated FcR g -Chain (1999) (10)
Therapeutic efﬁcacy of Fc g RI/CD64-directed bispeciﬁc antibodies in B-cell lymphoma (2000) (9)
Presence of CD 16 on Endothelial Cells in Heart Transplant Rejection: an Immunohistochemical Study (1992) (8)
The FcγRIIa-polymorphic site as a potential target for acute graft-versus-host disease in allogeneic stem cell transplantation (2005) (8)
Assignment of three human high-affinity Fcγ receptor I genes to chromosome 1, band q21.1 (2004) (8)
Experimental autoimmune myasthenia gravis in mice expressing human immunoglobulin loci (2003) (7)
Characterisation of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin’s lymphomas. (2004) (7)
Effect of rIFN‐γ on Antibody‐Mediated Cytotoxicity via Human Monocyte IgG Fc Receptor II (CD32) (1992) (7)
Fc (cid:2) RI (CD64) resides constitutively in lipid rafts (2008) (7)
Complement Activation and Complement-Mediated Killing of B Cells Promoted by Anti-CD20 Monoclonal Antibodies (mAb) Rituximab and Ofatumumab Are Rapid, and Ofatumumab Kills Cells More Rapidly and with Greater Efficacy. (2007) (6)
Molecular Basis for a Polymorphism of Human Fvy Receptor II ( CD 32 ) By (2003) (6)
Recombinant CD 64-Specific Single Chain Immunotoxin Exhibits Specific Cytotoxicity against Acute Myeloid Leukemia Cells (2003) (6)
Cell‐bound IgE and increased expression of Faɛ‐receptors on dendritic cells in cutaneous infiltrates of mycosis fungoides (1991) (5)
Ganglioside-specific IgG and IgA recruit leukocyte effector functions in Guillain–Barré syndrome (2007) (5)
Fully Human CD38 Antibodies Efficiently Trigger ADCC of Multiple Myeloma Cell Lines and Primary Tumor Cells. (2005) (4)
The cytoplasmic domain of Fc g RIIA (CD32) participates in phagolysosome formation (2001) (4)
Chemotherapy-refractory diffuse large B-cell lymphomas (DLBCL) are effectively killed by CD20 antibody-induced complement-mediated cytotoxicity (2011) (4)
Complement (C) Activation Followed by Penetration of the Membrane Attack Complex (MAC) on B Cells Opsonized with CD20 Mabs Allows for Calcium Influx Which Induces Streamers. Generalization of Streaming to Include other Mabs and Target Cells. (2008) (3)
IgG and complement receptor expression in children treated by peritoneal dialysis (2005) (3)
Protein 4.1G binds to a unique motif within the Fc (cid:2) RI cytoplasmic tail (2008) (3)
Spinning disk confocal fluorescent microscopy (SDCFM) analyses of complement activation promoted by anti-CD20 mAbs rituximab and ofatumumab (HuMax-CD20) (2007) (2)
[Immunology in clinical practice. X. IgG receptors: structure, function and immunotherapy]. (1998) (2)
Mimicking An Induced Self Phenotype by Coating Lymphomas with the Nkp30-Ligand B7-H6 Promotes Antitumoral Natural Killer Cell Cytotoxicity (2011) (2)
Granulocyte-Macrophage Colony-Stimulating Factor Induces Sequential Activation and Deactivation of Binding Via a Low-Affinity IgG Fc Receptor , hFcyRII , on Human Eosinophils (2003) (2)
FcR and autoimmunity (1998) (1)
HLA Class I 1 as Potential Target Antigen on Malignant B Cells for Therapy With Bispecific Antibodies in Combination With Granulocyte Colony-Stimulating Factor (2002) (1)
Role of ADCC in the in vivo antitumor effects of zalutumumab, a human anti-EGF receptor antibody. (2010) (1)
Fcγ Receptors of Myeloid Cells (1993) (1)
formation RIIA (CD32) participates in phagolysosome γ The cytoplasmic domain of Fc (2013) (1)
Expression of CD64 (FcγRI) in skin of patients with acute GVHD (2011) (1)
Ineffi cient antigen presentation via the IgA Fc receptor (FcαRI) on Dendritic Cells (2006) (1)
Bispeciffic antibody MDX210 (FcγRI × HER-2/neu) in combination with G-CSF: Results of a phase I trial in patients with metastatic breast cancer (1997) (1)
Anti-pneumococcal Antibodies in Mice Protection by Human IgG 1 and IgG 2 Central Role of Complement in Passive (2003) (0)
Novel antibody therapeutics for treatment of cancer and inflammation (2002) (0)
Transgenic Mice Potent Humoral Responses in Human CD64 Targeting Weak Antigens to CD64 Elicits (2000) (0)
CD 20-Directed Antibody Therapy Neutrophils as Effector Cells for-Receptor I ( CD 89 ) Recruits α Triggering FC (2000) (0)
Recurrent bacterial respiratory tract infections; IgG-subclasses, selective antipolysaccharide antibody deficiency and FcγRlla-receptor polymorphism (1997) (0)
Complement-dependent lysis of mAb-opsonized B cells can increase resistance of naive B cells to subsequent attack by mAb and complement (2010) (0)
Combined administration of G-CSF and anti-FcγRi bispecific antibodies generates HER2/neu-specific cytotoxic neutrophils (1997) (0)
F.117. FcγRiv Required for Succesfull Prevention of Liver Metastases Development After Antibody Therapy (2006) (0)
Affinity IgG Receptor , Fc Functional Characteristics of the High Winkel (2011) (0)
receptor, Fc{gamma}RI, in the presence of monomeric IgG Cytokine-induced immune complex binding to the high-affinity IgG (2010) (0)
Reply to Fab-arm exchange (2010) (0)
D/Anti-CD89 Protein Neutrophils via Chimeric Surfactant Protein Effective Targeting of Pathogens to (2004) (0)
Recombinant chimeric IgA1 and IgA2 antibodies for tumor immunotherapy (2007) (0)
Characteristics and Interrelation of 2 Types of Immunoglobulin-G Fc-Receptors on Human-Monocytes (1988) (0)
Fusion Proteins of Ligands for NKG2D and CD20-Directed ScFvs Sensitize Lymphomas for NK Cell-Mediated Lysis (2010) (0)
Anticorps monoclonaux anti-cd32b (2008) (0)
Antagonists That Inhibit IgG-Mediated R γ Homologue FLIPr-like Are Potent Fc like 1 Inhibitor (FLIPr) and Its - Receptor Formyl Peptide Staphylococcus aureus (2013) (0)
Receptor Receptor CD 89 and Consequences for Fc Signaling through Mutants of the IgA (2006) (0)
Syddansk Universitet CD 20-Specific Immunoligands Engaging NKG 2 D Enhance T Cell-Mediated Lysis of Lymphoma Cells (2017) (0)
Epitopes on CD 20 Monoclonal Antibodies Is Linked to Unique The Biological Activity of Human CD 20 (2006) (0)
B7-H6 Promotes NK Cell Cytotoxicity Coating Lymphomas with the NKp30 Ligand Mimicking an Induced Self Phenotype by (2012) (0)
Anti-P-selectin (2005) (0)
ReceptorAntibodies against Epidermal Growth Factor Effector Mechanisms of Recombinant IgA (2007) (0)
Effector proteins of the high affinity IgG receptor, CD64 (2006) (0)
Therapeutics , Targets , and Chemical Biology Cancer Research In vivo Cytotoxicity of Type I CD 20 Antibodies Critically Depends on Fc Receptor ITAM Signaling (2010) (0)
Human immunoglobulin A receptor (Fc alpha RI, CD89) as target for immunotherapy (2001) (0)
IgG-mediated anaphylaxis and inflammation are impaired in mice lacking FcγRIII (1997) (0)
Induced by OFA than by RTX Considerably Higher Levels of CDC Are Ofatumumab (OFA) or Rituximab (RTX): of B Cells Opsonized with Anti-CD20 mAbs Complement-Dependent Cytotoxicity (CDC) Binding of Submaximal C1q Promotes (2009) (0)
Antibody-Dependent Cellular Cytotoxicity Growth Factor Receptor Effectively Trigger Human IgG2 Antibodies against Epidermal (2009) (0)
Lung cancer-derived EGFR mutations affect responses to tyrosine kinase inhibitors, but not to monoclonal antibodies (2007) (0)
This information is current as EGFR Kinase Mutations Are Not Affected by Lung Cancer-Associated Growth Factor Receptor (EGFR) Antibodies Tumor Cell Killing Mechanisms of Epidermal (2013) (0)
Polymorphism and functioning of a low-affinity IgG Fc receptor, hFcγRII (CD32) (1992) (0)
Serogroup B meningitidis Neisseria Immune Defense Against Activity of Human IgG and IgA Subclasses in and (2001) (0)
222 Ofatumumab binds to a membrane-proximal epitope which comprises amino acids in the small and large loops of CD20 (2010) (0)
Direct Internalization by the B Cells Fc Receptor-Expressing Effector Cells Than Rapidly Because of Trogocytosis Mediated by from Opsonized B Cells Occurs More Loss of CD20 and Bound CD20 Antibody (2011) (0)
Binding characteristics of human serum IgA to CD89 (1997) (0)
Induction and effector phase of experimental allergic encephalomyelitis are independent of the Fc gamma chain (2004) (0)
Metastases Reveals Functional Redundancy Experimental Antibody Therapy of Liver (2008) (0)
Myeloid Lineage but , in Contrast to IgG 1 , Only by Cells of Antibody-Dependent Cellular Cytotoxicity Growth Factor Receptor Effectively Trigger Human IgG 2 Antibodies against Epidermal (2009) (0)
Role of FcRn in phagocytes (2006) (0)
MolecularBasisfora Polymorphism ofHuman Fvy ReceptorII(CD32) (1990) (0)
Recombinant Dimeric IgA Antibodies as Tumor-Specific Agents. (2010) (0)
Antibodies to factor receptor I insulin-like growth and use thereof (2004) (0)
Bordetellapertussisattachment to respiratory epithelial cells can be impaired by ¢mbriae-speci¢c antibodies (2005) (0)
Mediate Effective Tumor Cell Killing the Epidermal Growth Factor Receptor Recombinant Dimeric IgA Antibodies against (2011) (0)
Candidate targets for antibody therapy of rheumatoid arthritis: CD64 and IL-15 (2003) (0)
-Chain Interaction g Receptor Receptor CD89 and Consequences for Fc Signaling through Mutants of the IgA (2006) (0)
252Type I CD20 antibodies take over the B-cell receptor for complement-dependent cytotoxicity (CDC) of malignant B cells (2012) (0)
Human monocyte FcÚ receptors (1988) (0)
Cytokine-induced immune complex binding to the high-afﬁnity IgG receptor, Fc (cid:1) RI, in the presence of monomeric IgG (2010) (0)
Effect of combinations of EGF-R antibodies on complement-dependent tumor cell lysis (2008) (0)
FcγRI receptor complexes in mouse B-cells trigger phagocytosis, cytokine production and ADCC (1997) (0)
Hematological Tumors of Multiple Myeloma and Other CD38 Monoclonal Antibody, Induces Killing Daratumumab, a Novel Therapeutic Human (2010) (0)
A New Human CD20 Antibody for Improved Killing of CD20-Transgenic T Cells for Allogeneic Stem Cell Transplantation. (2005) (0)
Chimeric IgA antibodies for lymphoma therapy (2001) (0)
Development of an Effective Safety Switch for Selective Elimination of Human T Cells In Vivo after Adoptive Transfer. (2006) (0)
Activity in Palmoplantar Pustulosis ClinicalInflammatory Diseases : Reduction of IL-8 as Antibody Therapeutic Target in (2008) (0)
Boosting ADCC activity of therapeutic antibodies by concomitant stimulation of Fc gamma RIIIa and activating NK cell receptors (2015) (0)
Effector proteins of Fc{gamma}RI: inside-out and outside-in regulation (2009) (0)
The Novel Bispecific Antibody [(CD20) 2 xCD16] Efficiently Triggers Lysis of Neoplastic B Cells (2010) (0)
Fc receptors: historical perspectives and a look to the future (1998) (0)
Mechanisms of cooperation of Fc-alpha-RI (CD89) and Mac-1 (CD11b/CD18) in tumor cytotoxicity; implications for immunotherapy (2002) (0)
Anticorps igg4 stables (2008) (0)
428. Development of an Effective Safety Switch for Selective Elimination of Human T Cells In Vivo after Adoptive Transfer (2006) (0)
Spinning Disk Confocal Fluorescent Microscopy (SDCFM) Analyses of Complement Activation Promoted by Anti-CD20 Monoclonal Antibodies (mAbs) Rituximab and Ofatumumab. (2007) (0)
Spinning Disk Confocal Fluorescent Microscopy (SDCFM) Analyses of Complement Activation Promoted by Anti-CD20 Monoclonal Antibodies (mAbs) Rituximab and Ofatumumab. (2007) (0)
BISPECIFIC ANTIBODIES AND CYTOKINE-STIMULATED EFFECTOR CELLS: NEW OPTIONS FOR IMMUNOTHERAPY OF RENAL CELL CARCINOMA (1999) (0)